Related Experiment Video
Updated: Jun 5, 2025
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
994
Rationale and concerns for using JAK inhibitors in axial spondyloarthritis
Saad Ahmed1, Rohan Yesudian2, Hassan Ubaide1
1General Medicine, Colchester Hospital, Colchester, UK.
Rheumatology Advances in Practice
|December 11, 2024
Summary
Janus kinase (JAK) inhibitors offer new treatment options for axial spondyloarthritis (axSpA), showing promise for patients unresponsive to current therapies. Further research is needed to confirm long-term efficacy and safety, especially in non-radiographic axSpA.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Axial spondyloarthritis (axSpA) is a chronic inflammatory condition with limited therapeutic choices.
- Janus kinase (JAK) inhibitors represent a novel therapeutic class with a distinct mechanism of action for axSpA.
Purpose of the Study:
- To review the efficacy and safety of JAK inhibitors in treating axSpA.
- To summarize data from Phase 2 and 3 clinical trials of tofacitinib, upadacitinib, and filgotinib in axSpA.
Main Methods:
- Systematic review of current Phase 2 and 3 clinical trial data for tofacitinib, upadacitinib, and filgotinib.
- Assessment of safety profiles, including emerging safety signals from studies like the ORAL Surveillance study.
Main Results:
- JAK inhibitors demonstrate potential efficacy in axSpA, addressing unmet needs for patients with inadequate response or contraindications to existing treatments.
- Data from trials involving tofacitinib, upadacitinib, and filgotinib are summarized, highlighting their therapeutic roles.
Conclusions:
- JAK inhibitors provide a novel therapeutic avenue for axSpA, potentially improving outcomes for specific patient populations.
- Further long-term studies are required to fully establish the efficacy and safety of JAK inhibitors, particularly in non-radiographic axSpA.
Keywords:
Janus kinase inhibitorsankylosing spondylitisaxial spondyloarthritis managementnon-radiographic axial spondyloarthritisradiographic axial spondyloarthritisspondyloarthropathiesMore Related Videos
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
115
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
115
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
385
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
385
01:29Inflammatory Bowel Disease IV: Pharmacological Management
112
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
112
01:25Antihypertensive Drugs: Direct Renin Inhibitors
490
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
490
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K